REDWOOD CITY, Calif.--(BUSINESS WIRE)--EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools. This latest addition to EditCo Bio’s product lineup marks a significant leap forward in CRISPR-mediated gene editing, providing the scientific community with an advanced tool for primary T-cell editing that surpasses the capabilities of traditional methodologies..

加利福尼亚州红木城（商业新闻短讯）--基因组工程创新前沿的先驱EditCo Bio，Inc.今天宣布推出其基因敲除CD4+T细胞库。EditCo Bio产品系列的最新添加标志着CRISPR介导的基因编辑取得了重大飞跃，为科学界提供了一种先进的初级T细胞编辑工具，超越了传统方法的能力。。

With the advent of CRISPR-Cas9 technology, genetic engineering has entered a new era of precision, particularly in the realm of primary immune cell editing. T-cells, pivotal in the immune response, hold immense promise for elucidating the pathways of various diseases, including cancer and autoimmune conditions.

随着CRISPR-Cas9技术的出现，基因工程进入了一个精确的新时代，特别是在原代免疫细胞编辑领域。在免疫反应中起关键作用的T细胞在阐明各种疾病（包括癌症和自身免疫性疾病）的途径方面具有巨大的前景。

Yet, conventional T-cell editing techniques have often fallen short, plagued by scalability issues and inconsistent outcomes..

然而，传统的T细胞编辑技术往往不足，受到可扩展性问题和不一致结果的困扰。。

Leveraging the power of EditCo Bio’s cutting-edge, automated platform, researchers can now bypass the challenging optimization steps and access highly functional edited T-cells ready for immediate use. This innovation not only accelerates the journey from research discovery to clinical application but also delivers several key benefits:.

利用EditCo Bio的尖端自动化平台的强大功能，研究人员现在可以绕过具有挑战性的优化步骤，访问功能强大的编辑过的T细胞，随时可用。这一创新不仅加速了从研究发现到临床应用的旅程，而且还带来了几个关键好处：。

Rapid Results: A novel 7-day protocol harnesses EditCo Bio’s unique multi-guide technology to achieve knockout efficiencies beyond 90% in primary human CD4+ T-cells.

快速结果：一种新颖的7天方案利用EditCo Bio独特的多导向技术，在原代人CD4+T细胞中实现超过90%的敲除效率。

Dependable Performance: Post-editing, CD4+ cell pools maintain over 80% viability before cryopreservation and can expand 40-fold over 14 days, regardless of TCR stimulation.

可靠的性能：编辑后，CD4+细胞库在冷冻保存前保持超过80%的活力，并且无论TCR刺激如何，都可以在14天内扩大40倍。

Optimal Functionality: After cryo-recovery, these CD4+ T-cell pools exhibit remarkable functional integrity, matching control cells in IL2, IFNG, and TNFA protein production post-PMA/ionomycin stimulation. Further, cultured cells retain over 90% viability and maintain editing efficiency for at least 14 days..

最佳功能：冷冻恢复后，这些CD4+T细胞库表现出显着的功能完整性，与PMA/离子霉素刺激后IL2，IFNG和TNFα蛋白产生中的对照细胞相匹配。此外，培养的细胞保持90%以上的活力，并保持编辑效率至少14天。。

'For too long, the potential of primary T-cell editing has been constrained by the technical limitations of existing methods,” said Travis Maures, CSO of EditCo Bio. “With the launch of our Knockout CD4+ T-cell Pools, EditCo Bio is breaking down these barriers, offering researchers the precision, efficiency, and scalability needed to advance the frontiers of immunotherapy and cellular research while allowing them the benefit of bypassing tedious protocol optimization.

EditCo Bio的CSO Travis Maures说：“长期以来，原代T细胞编辑的潜力一直受到现有方法的技术限制。随着我们的敲除CD4+T细胞库的推出，EditCo Bio正在打破这些障碍，为研究人员提供推进免疫治疗和细胞研究前沿所需的精确度，效率和可扩展性，同时使他们能够绕过繁琐的协议优化。

This innovation is a testament to our commitment to empowering scientists worldwide, driving forward the possibilities of gene editing to address some of the most pressing challenges in research today.'.

这项创新证明了我们致力于增强全世界科学家的能力，推动了基因编辑的可能性，以应对当今研究中一些最紧迫的挑战。”。

The introduction of Knockout CD4+ T-cell Pools is a strategic extension of EditCo Bio’s comprehensive Engineered Cell portfolio. It further solidifies the company’s position as a leader in cell engineering solutions that includes knockout and knock-in technologies for immortalized cells and iPSCs. EditCo Bio plans to expand the range of its edited primary cells products beyond CD4+ T-cells into other primary cell subsets that will be commercially available to researchers worldwide later this year..

基因敲除CD4+T细胞库的引入是EditCo Bio综合工程细胞组合的战略延伸。它进一步巩固了该公司在细胞工程解决方案（包括永生化细胞和iPSC的敲除和敲入技术）领域的领先地位。EditCo Bio计划将其编辑的原代细胞产品的范围从CD4+T细胞扩展到其他原代细胞亚群，这些亚群将于今年晚些时候在全球范围内商业上提供给研究人员。。

For more information regarding EditCo Bio’s CD4+ T-cell Pools, visit www.EditCo.bio/contact.

有关EditCo Bio的CD4+T细胞库的更多信息，请访问www.EditCo.Bio/contact。

About EditCo Bio, Inc.

关于EditCo Bio，Inc。

EditCo Bio is a pioneer in the development of cells as reagents. The company began as the gene editing business at Synthego and, through that experience, has gained a deeper understanding of the critical role that high-quality, easily accessible reagents play in advancing scientific discoveries. EditCo is bringing the same ease of ordering, reliability, and rapid delivery to the biology of engineered cells.

EditCo Bio是开发细胞作为试剂的先驱。该公司最初是Synthego的基因编辑业务，通过这一经验，该公司对高质量，易于获得的试剂在推进科学发现中的关键作用有了更深入的了解。EditCo为工程细胞的生物学带来了同样的订购方便，可靠性和快速交付。

This new direction promises to transform how engineered cells are accessed and utilized in research, making them as efficacious and as reproducible as traditional reagents. To learn more about EditCo Bio, visit our website at www.EditCo.bio..

这一新方向有望改变工程细胞在研究中的获取和利用方式，使其与传统试剂一样有效和可重复。要了解有关EditCo Bio的更多信息，请访问我们的网站www.EditCo.Bio。。